Search results for

Antti Papula and Perja Papula of Nevinpat in Helsinki explain that Russian patent practice differs from that of Europe. This is particularly true for claims relating to chemical and medical compounds

In the 10 years since the rebirth of democracy, Romania has made major progress. But counterfeiting of IP rights has escalated. Lucien Enescu and Ian Mocanu of Rominvent in Bucharest explain how the problem has arisen and what measures are being taken to defeat it

Romania has a new law governing the protection of plant varieties. Lucian Enescu and Cristina Popa of Rominvent in Bucharest explain how to obtain protection

Japan’s domain name system has seen fundamental changes in the past year. Yasuyoshi Goto and Ari Staiman, of Tokyo Aoyama Aoki/Baker & McKenzie in Tokyo, examine the recently introduced changes

Judith Kerény, of Danubia Patent & Trademark Attorneys in Budapest, discusses some of the challenges of pharmaceutical patent litigation in Hungary

Dr Bernhard Fischer, of Bardehle Pagenberg Dost Altenburg Geissler Isenbruck in Munich, examines recent developments on the use of research tool patents in Germany

The Czech Republic has modified its IP laws to harmonize with the European Union. Karel Cermak, of Cermak Horejs Myslil in Prague explains the changes

France: Lovells will merge with French firm Siméon & Associés, effective November 1. The combined Paris office will have 25 partners and more than 80 other attorneys.

One of the most fundamental biotechnology inventions is due to be tested in a Massachusetts district court, after Applied Molecular Evolution (AME) filed a patent infringement suit against Morphosys on June 26. AME owns a licence to six patents filed by Stuart Kauffman covering directed evolution technology. The patents have been described by Nature Biotechnology magazine as being as important as those filed by Cohen and Boyer in the first generation of biotechnology.

There are an estimated 190 core biotech and 460 biotech-related companies operating in Australia Approximately 35 core biotech companies and 25 biotech-related companies are publicly listed The industry as a whole has raised about A$900 million since the previous industry report in 1999, five times more than estimated in 1998-1999 Revenues generated by core biotech companies over the past 12 months are estimated at almost A$1 billion. Human health, equipment and services, and agriculture are the sectors with the most number of products under development. In 2001 there is an estimated A$300 million of ongoing publicly funded research in biotechnology Victoria has the greatest number of core biotechnology companies (38%) New South Wales has the highest number of biotech-related companies (40%) R&D investment by Australian biotech companies in 1999-2000 was approximately A$150 million. Approximately half the biotech companies operate in the human health sector, including diagnostics and therapeutics Genomics and bio-informatics companies has more than doubled since 1999 Australia's patent system gives it a competitive advantage in attracting foreign companies to invest in the country's biotechnology industry, according to a recently released report on the growth of the sector.